

Melatonin, Immune Function and Cancer

Venkatramanujam Srinivasan^{1,2} Seithikurippu R. Pandi-Perumal³ Amnon Brzezinski⁴ Kunwar P. Bhatnagar⁵ and Daniel P. Cardinali⁶

¹Sri Sathya Sai Medical Educational and Research Foundation, Prasanthi Nilayam, 40- kovai Thirunagar, Coimbatore, India, ²Department of Physiology, Karpagam Medical College & Hospital, Karpagam University, Etchanar, Coimbatore, India, ³Somnogen Inc, New York, 11418-2317, USA, ⁴Department of Obstetrics and Gynecology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel, ⁵Department of Anatomical Sciences and Neurobiology, University of Louisville, Louisville, Kentucky, USA, ⁶Departamento de Docencia e Investigación, Facultad de Ciencias Médicas, Pontificia Universidad Católica Argentina 1107 Buenos Aires, Argentina

Received: June 29, 2010; Accepted: November 11, 2010; Revised: November 22, 2010

Abstract: Melatonin is a natural substance ubiquitous in distribution and present in almost all species ranging from unicellular organisms to humans. In mammals, melatonin is synthesized not only in the pineal gland but also in many other parts of the body, including the eyes, bone marrow, gastrointestinal tract, skin and lymphocytes. Melatonin influences almost every cell and can be traced in membrane, cytoplasmic, mitochondrial and nuclear compartments of the cell. The decline in the production of melatonin with age has been suggested as one of the major contributors to immunosenescence and development of neoplastic diseases. Melatonin is a natural antioxidant with immunoenhancing properties. T-helper cells play an important role for protection against malignancy and melatonin has been shown to enhance T-helper cell response by releasing interleukin-2, interleukin-10 and interferon- γ . Melatonin is effective in suppressing neoplastic growth in a variety of tumors like melanoma, breast and prostate cancer, and ovarian and colorectal cancer. As an adjuvant therapy, melatonin can be beneficial in treating patients suffering from breast cancer, hepatocellular carcinoma or melanoma. In this paper, a brief review of recent patents on melatonin and cancer has also been presented.

Keywords: Melatonin, melanoma, immune therapy, oxidative stress, breast cancer, prostate cancer, gastrointestinal cancer, colorectal cancer, cytokines, T-helper cells.

INTRODUCTION

Melatonin is a natural substance that has been identified in all major living species, including bacteria and other unicellular microorganisms, plants and animals, as well as in humans [1,2]. It is possible that the first function of melatonin in phylogeny was related to its activity as a direct and indirect antioxidant. Interestingly enough, several herbs that contain high levels of melatonin have been used by Chinese since ancient times to retard ageing and to treat diseases associated with the generation of free radicals [3].

Both ageing and free radical generation are major factors involved in all steps of carcinogenesis, including initiation, promotion and progression of neoplastic disease [4]. The ubiquitous distribution of melatonin in Nature is compatible with the view that, being an effective antioxidant [5], it can be one of the natural molecules that are effective in treating neoplastic [6-10] as well as degenerative diseases [11,12].

Melatonin is normally synthesized and secreted during the dark phase of daily photoperiod. Though it is produced primarily in the pineal gland, melatonin is also synthesized

in other organs like the retina, bone marrow cells, gastrointestinal (GI) tract, lymphocytes, platelets and skin (see for ref. [2]). Reports on plasma melatonin levels among subjects of different age groups reveal a decrease in melatonin production with advanced age [13].

Ageing is associated with a decline in immune function known as immunosenescence. This leads to increased susceptibility to infectious diseases and cancer. The decline in circulating levels of hormones associated with ageing such as dehydroepiandrosterone, estradiol, growth hormone and melatonin has been suggested to contribute to immunosenescence [14]. Pineal ablation, or any other experimental procedure that inhibits melatonin synthesis and secretion, induces a state of immunodepression, which is partly counteracted by melatonin administration [7,15-17]. The immunoenhancing action of melatonin is demonstrable in a variety of animal species and in humans.

Among the various functions attributed to melatonin in the control of the immune system, antitumor defense assumes a primary role [18-21]. The nighttime physiological surge of melatonin in the blood or extracellular fluid has been suggested to serve as a "natural restraint" for tumor initiation, promotion and/or progression [6]. Melatonin was demonstrated to be oncostatic for a variety of tumor cells like breast carcinoma [22-24], ovarian carcinoma [25], endometrial carcinoma [26], human uveal melanoma cells [27], prostate tumor cells [28] and GI tumors [29,30].

*Address correspondence to these authors at the Director, Departamento de Docencia e Investigación, Facultad de Ciencias Médicas, Pontificia Universidad Católica Argentina, Av. Alicia Moreau de Justo 1500, 4 piso, 1107 Buenos Aires, Argentina; Tel: +54 11 43490200; Ext: 2310; Fax: +54 11 43380720; E-mails: danielcardinali@uca.edu.ar; danielcardinali@fibertel.com.ar

MELATONIN BIOSYNTHESIS

Melatonin is synthesized from the amino acid tryptophan *via* its conversion to serotonin. Serotonin is then acetylated to form N-acetylserotonin by the enzyme arylalkylamine N-acetyltransferase (AANAT). N-acetylserotonin is converted into melatonin by the enzyme hydroxyindole-O-methyltransferase (HIOMT). The enzymatic machinery for melatonin biosynthesis was first identified by Axelrod in the pinealocytes [31] and has been subsequently identified in the retina, bone marrow cells, GI tract, skin, lymphocytes and platelets (see for ref. [2]). Pineal melatonin production exhibits a circadian rhythm with low levels during daytime and high levels during night. This circadian rhythm occurs in most living organisms irrespective of whether they are diurnally or nocturnally active.

The regulation of pineal melatonin biosynthesis by ambient illumination is mediated by the retinohypothalamic tract that projects from the retina to the suprachiasmatic nucleus (SCN), the major circadian oscillator Fig. (1) [32]. Special photoreceptive retinal ganglion cells are the origin of that retinohypothalamic projection [33]. These ganglion cells contain a special photosensitive pigment, known as melanopsin, which is involved in the phototransduction mechanism [34].

Nerve fibers from the SCN project to a multisynaptic descending pathway that passes through the paraventricular nucleus, medial forebrain bundle and reticular formation and makes synaptic connections with intermediolateral cells of the cervical spinal cord. From there, preganglionic fibers project to the superior cervical ganglia where postganglionic sympathetic fibers innervating the pineal gland are located, regulating pineal melatonin synthesis by releasing norepinephrine (NE) at their postganglionic nerve terminals [32].

The release of NE from pineal nerve terminals occurs during nighttime. NE, by binding to β -adrenergic receptors at the pinealocyte membrane, activates G-protein subunits to stimulate adenylate cyclase activity and the subsequent cyclic AMP (cAMP) production. The increase of cAMP promotes the synthesis of enzymes involved in melatonin biosynthesis [35].

Circulating melatonin derives almost totally from the pineal gland, as shown by the fact that undetectable melatonin levels are found after pinealectomy. After its release, melatonin is bound to albumin [36] and reaches all tissues within a very short period [37,38]. Melatonin's half-life is biexponential with a first distribution half-life of 2 min and a second of 20 min.




Fig. (1). Circadian regulation. Light impinging on the eye send neural signals to a population of receptive neurons in the suprachiasmatic nuclei (SCN) *via* the retinohypothalamic tract (RHT). The SCN in turn acting *via* a complex indirect multisynaptic pathway including projections to the intermediolateral column (ILC) of the cervical spinal chord and the superior cervical ganglion (SCG), sends a circadian signal to the pineal gland (PIN) regulating synthesis of melatonin. Melatonin feeds back on the SCN as well as on numerous other brain sites that contain melatonin receptors.

Melatonin metabolism occurs mainly in the liver, where it is first hydroxylated in the C6 position and then conjugated with sulfate and excreted as 6-sulfatoxymelatonin. In many cells it is converted into cyclic 3-hydroxymelatonin after scavenging two hydroxyl radicals [39]. Melatonin is also metabolized into kynuramine derivatives [40]. It is interesting to note that the antioxidant properties of melatonin are shared by some of their metabolites like *N*¹-acetyl-5-methoxykynuramine (AMK) and *N*¹-acetyl-*N*²-formyl-5-methoxykynuramine (AFMK) [41]. Thus melatonin gives rise to a cascade of antioxidant molecules that multiply the free radical scavenger effect Fig. (2).

As melatonin diffuses through all biological membranes with ease, it is localized in membrane, cytoplasmic, mitochondrial and nuclear compartments [42]. Depending upon its production site and target organ, melatonin acts as a hormone, autacoid, chronobiotic, hypnotic, immunomodulator or as a biological modifier.

MELATONIN RECEPTORS

Melatonin exerts some of its actions through interaction with MT₁ and MT₂ receptors [43,44]. These membrane receptors have seven intramembrane domains and belong to the superfamily of G- protein coupled receptors. A third

binding site, identified initially as MT₃, was subsequently characterized as the enzyme quinone reductase 2 [45].

Many G protein-coupled receptors, including the MT₁ and MT₂ receptors, exist in living cells as dimers. The relative propensity of the MT₁ homodimer and MT₁/MT₂ heterodimer formation are similar whereas that of the MT₂ homodimer is 3-4 fold lower [46,47]. It is of interest that a receptor that shares 45% of the amino acid sequence with MT₁ and MT₂ but does not bind melatonin (called GPR50, [48]), abolishes high affinity binding of the MT₁ receptor through heterodimerization [49,50]. Thus the GPR50 receptor may have a role in melatonin function by altering binding to the MT₁ receptor.

Melatonin also acts by binding to cytoplasmic proteins like the calcium binding protein calmodulin [51] or tubulin [52], and to nuclear receptors like RZR/ROR [53]. The melatonin receptor present in the skin has been identified as MT₁ [54]. MT₂ receptors have been detected in neonatal keratinocytes, and in cutaneous melanoma cell lines as well as in normal and malignant uveal melanocytes [55].

The decrease in cAMP production caused by melatonin via MT₁ and MT₂ receptor interaction decreases the uptake of linoleic acid, an essential fatty acid, by affecting a specific fatty acid transporter [56]. Linoleic acid can be oxidized to




Fig. (2). The pleiotropy of melatonin: an overview of several major actions. Abbreviations: AFMK = *N*¹-acetyl-*N*²-formyl-5-methoxykynuramine; AMK = *N*¹-acetyl-5-methoxykynuramine; c3OHM = cyclic 3-hydroxymelatonin; mtPTP = mitochondrial permeability transition pore; ROR α , RZR β = nuclear receptors of retinoic acid receptor superfamily. (Reprinted with permission from [2]).

13-hydroxyoctadecadienoic acid by 15-lipoxygenase, serving as an energy source for tumor growth and tumor growth-signaling molecules. Inhibition of linoleic acid uptake by melatonin is regarded as a mechanism of its antiproliferative effects [56].

Some studies have also suggested modulations in the expression and function of nuclear receptors, RZR/ROR, as the mechanism for biological effects of melatonin. By binding to nuclear receptors, melatonin alters the transcription of several genes that play a role in cellular proliferation (e.g., 5-lipoxygenase, p21, or bone sialoprotein) [57].

Another mechanism of the biological effects of melatonin may be its ability to modulate intracellular calcium and calmodulin activity. Calcium-activated calmodulin is involved in the initiation of the S and M phases of the cell cycle, cell cycle-related gene expression, and the reentry of quiescent cells from G₀ back into the cell cycle [56]. Melatonin has been shown to increase calmodulin degradation due to direct binding as well as causing redistribution of calmodulin, thereby inhibiting cell cycle progression [51].

Melatonin also serves as a potent modulator of gene transcriptional activity. Conventional approaches have allowed identification of a large number of genes, targeted by melatonin centrally (in brain structures, most importantly in SCN and in pars tuberalis of the hypophysis), or in peripheral tissues. Discovering the mechanisms of melatonin interaction with clock genes (*Per*, *Clock*, *Bmal* and others) could be considered as one of the major achievements of these studies. It has been hypothesized that melatonin mediate seasonal photoperiodic control *via* the phasing of expression of clock genes in the pars tuberalis, with a length of the melatonin signal decoded in target tissues in a form of the clock gene expression profile signatures (“internal coincidence model” [58]).

Progress in a development of DNA microarray technology has increased the list of possible melatonin targets in peripheral tissues. Microarray-based screening of about 8000 rat cDNA clones have led to the identification of a limited group of genes with expression in rat neural retina and retinal pigmentary cells that were changed significantly by melatonin [59]. In neural retina, treatment with melatonin stimulated the expression of 6 genes and repressed the expression of 8 genes, while in retinal pigmentary cells 15 genes were up-regulated and 2 were down-regulated. Among these genes, some with important physiological functions were present. For example, melatonin down-regulated gene expression of integrin and integrin-associated protein-encoding genes in rat retina, while the cAMP response element binding protein (CREB) gene was up-regulated in retinal pigmentary cells [59].

In mice administered melatonin in drinking water, total RNA purified from cardiac tissue was used to synthesize isotope-labeled probes which were subsequently hybridized to microarrays [8]. Analysis of the microarray data indicated a limited group of transcripts (212, <1.4% of the clones screened) with significantly altered cardiac gene expression. Among these, 146 genes were up-regulated and 66 down-regulated.

Although melatonin affected the expression of a wide spectrum of genes, its primary effectors tended to be associated with the genes controlling the cell cycle, adhesion, and transport. This finding is in agreement with the established data on the effect of melatonin on cell proliferation, apoptosis, and adhesion. Notably, melatonin has also demonstrated a pronounced effect on the expression of genes related to oncogenesis (e.g., *Mybl1*, *Rasa1*, *Mllt3* and *Enigma homolog 2*) and calcium metabolism (*Kcnn4* and *Dcamk11*) [8].

A significant effect of melatonin on expression of mitochondrial genes was also revealed, like genes encoding 16S ribosomal RNA (*mt-Rnr2*), cytochrome C oxidase subunits I and III (*mt-Co1*, *mt-Co3*) and NADH dehydrogenase 1 (*mt-Nd1*) (all up-regulated) and ATP synthase subunit 6 (*mt-Atp6*; down-regulated) [8]. This finding supports previous observations of the direct effect of melatonin upon the expression of mitochondrial genome-encoded genes in the brown adipocytes of Siberian hamster [60].

AGING, IMMUNE FUNCTION AND CANCER

That the levels of immunity is a predictor of individual longevity in human beings has been suggested by several epidemiological studies like OCTO and NONA [61] which reveal the existence of “immunological risk phenotypes” that can predict the life span in the elderly [62-64]. Longer life in centenarians has been associated with high natural killer (NK) cell number, augmented interferon (IFN)- γ production and phagocytosis [65,66]. The age-associated increases in NK cells were interpreted as a compensatory response to overcome the decreased immune function that could otherwise trigger neoplastic growth [67].

Studies of knockout mice have shown the important role of immune system in controlling the spontaneous generation of tumors. Nearly 50% of aged IFN- γ ^{-/-} or perforin^{-/-} mice developed lymphomas, lung adenocarcinoma or sarcoma [68]. Immune changes during aging may result in tumor growth since the incidence of metastatic cancer at autopsy peaks at 75- 90 years and has been shown to decline in 95-99 year old and centenarians [69]. That the personality and the emotional state of the individual can influence the course of illness by altering the immune function has been well documented [70,71].

The understanding of the immune changes in the elderly can provide new insights into the complex relationship between immunity and cancer. In this respect, the decline in the production of melatonin with aging was suggested to play an important role in triggering immunosenescence, especially age-associated neoplastic diseases [7].

Any search for a therapeutic agent that can improve the quality of life in the elderly depends upon the identification of substances that have both antioxidant and immunoenhancing qualities. As melatonin has been identified as a natural chronobiotic substance with antioxidant with immunoenhancing properties, it has the potential of becoming an effective therapeutic substance in preventing or arresting neoplastic growth.

MELATONIN IN IMMUNE MECHANISMS

There are many natural mechanisms that protect against carcinogenesis and they fall into two main categories, immune and non-immune. Among the former, immunosurveillance has been suggested as one of the major processes by which cancerous cells are detected and eliminated [72]. The activation of lymphocytes and monocytes/macrophages by melatonin can be one of the major mechanisms in preventing tumor development [21]. Melatonin has a significant immunomodulatory role in the immunocompromised state [73]. The age-related impairment of the immune system first appears around the sixth decade of age coinciding with a normal decrease in plasma melatonin concentration. Aging is associated with a decline in immune function that predisposes to increased incidence of cancer and infectious and neurodegenerative diseases like Alzheimer's disease.

The diurnal and seasonal changes in the immune function correlate with melatonin biosynthesis and secretion [74]. In addition, the synthesis of melatonin by human lymphocytes [75] lend support to the hypothesis that melatonin has a role in the regulation of immune function. Other studies demonstrated that the melatonin synthesized by human T cells contributes to regulation of interleukin (IL)-2 production acting as an intracrine, autocrine and/or paracrine substance [76]. The presence of high levels of melatonin in cultured rat thymocytes and expression of mRNAs encoding for AANAT and HIOMT in the rat and human thymus cells support that melatonin is also synthesized by thymocytes [77].

Seasonal changes of melatonin secretion are observed in human beings [78] and it is suggested that melatonin has significant role in immune modulation during different seasons of the year [79]. The role of melatonin as a possible mediator of seasonal changes effects on immune function has been well documented [80,81].

Melatonin receptors are detectable in the monocyte/macrophage lineage [82]. Administration of melatonin increases the production of both monocytes and NK cells in bone marrow and spleen within 7-14 days of treatment [83]. As both cell types are components of the non-specific immune system, the findings suggest that melatonin can be effective in arresting neoplastic growth and in destroying virus infected cells. Melatonin's stimulatory action on monocyte production could be due either to its direct action on melatonin receptors in monocytes or to its sensitizing action on monocytes to stimulants like IL-3, IL-4 or granulocyte-macrophage-colony stimulating factor [83,84]. By this action melatonin was able to rescue hematopoiesis from the toxic effect of cancer chemotherapy in several experimental models [85]. This evidence actually poses the basis for the therapeutic use of melatonin as an adjuvant in combination with myelotoxic anti-cancer therapeutic protocols.

NK cells play an important role in immunosurveillance against neoplasia and virus infected cells. Acute administration of melatonin increased NK cell responsiveness to IFN- γ while its chronic administration not only augments NK cell activity but also increases the number of NK cells in circulation [86]. The increased NK cell number brought out

by melatonin is attributed to an increased production of cytokines like IL-2, IL-6, IL-12 and IFN- γ from T helper (Th)-1 lymphocytes and from monocytes [83,87]. The presence of melatonin receptors on T lymphocytes explains melatonin's action in releasing cytokines that enhance the NK cell activity and augment NK cell number. By activating Th-1 cells melatonin enhances the production of IFN- γ [88]. Melatonin's immunoenhancing effect depends not only upon its ability to enhance the production of cytokines but also upon its antiapoptotic and antioxidant actions Fig. (2).

MELATONIN AND T LYMPHOCYTES

Th lymphocytes play an important role for protection against malignancy, by recruiting cells of the immune system and by activating antigen-specific effector cells [89,90]. Importance has been given to the stimulation of CD4⁺ Th cell in cancer chemotherapy. CD4⁺ lymphocytes secrete IFN- γ and tumor necrosis factor (TNF)- α that activate and regulate cytotoxic T cell responses. Melatonin treatment augmented CD4⁺ cells in lymph nodes of rats [91]. Th-1 cells directly kill tumor cells by releasing cytokines that activate "death" receptors on the tumor cell surface [90]. Melatonin also favors Th-2 responses: it not only stimulates the release of IFN- γ and IL-2 but also of IL-10 [92].

In immunodepressed states, melatonin's immunoenhancing action is restricted to T-lymphocytes [15]. Since the proinflammatory cytokine inhibits nocturnal pineal melatonin production [93], the results suggest that during the response to an injury the production of melatonin can be transiently shifted from an endocrine (pineal) to a paracrine (immunocompetent cells) source [94].

MELATONIN IN MELANOMA

Melanocytes in the skin are involved in the production of melanin pigment; in the adult skin, they exhibit only intermittent mitotic activity. Under certain conditions, such as exposure to UV radiation or during the process of wound healing, their mitotic activity increased several-fold. That proliferative response depends upon the delicate balance between positive and negative cell cycle regulatory signals and alteration of these signals can result in uncontrollable cell division and malignancy [95].

UV radiation of the skin promotes the production and release of photoprotective melanin pigments *via* the α -melanocyte-stimulating hormone receptor system and the p53 transcription factor. This activates the cAMP pathway to initiate a series of events that culminate in increased melanin synthesis [95]. The UV-irradiated melanocytes also express elevated concentrations of inhibitor kinase (INK) 4 cyclin-dependent kinases (cdk) inhibitor, p16^{ink4a}. This inhibits the cyclin D3/cdk4, a complex that is essential for cell cycle progression through G2 phase to meiosis. Inhibition of this phenomenon by p16^{ink4a} delays the G2 phase progress, thus promoting melanoma [95].

The fact that melanoma cells express antigens that can be recognized by T cells, that T cells can destroy melanoma cells, and that exposure of the skin to UV radiation causes immunosuppression suggests that the immune response has an important effect in melanoma development [96]. Cytotoxic T

cells that specifically destroy melanoma cells have been identified in the blood of patients with melanoma [97]. UV radiation enhances the growth of melanoma by inhibiting the infiltration of melanoma by T cells [98].

Melatonin acts as a protective agent against damage induced by UV radiation in the human skin [99]. Melatonin is also radioprotective against X-ray induced skin damage in the albino rat [100]. The radioprotective action of melatonin is attributed to its antioxidant properties [101] *via* direct radical scavenging properties and stimulation of antioxidant enzymes as demonstrated in human skin fibroblasts Fig. (2) [102].

Melatonin has oncostatic properties in melanomas and tumors of epithelial origin [103,104]. The ability of melatonin to stimulate IL-2 production and to enhance its antitumor activity has been tested both in experimental animals and in clinical trials. Melatonin on its own exerted a significant antitumor effect but when combined with IL-2 it potentiated the antitumor effect of IL-2 in an additive manner [105,106]. In cancer patients both T and NK cells are generally depressed, and since melatonin can augment the production of T lymphocytes and NK cells *via* IL-2 increase, melatonin administration could be a useful adjuvant therapy to impair tumor growth [107].

Melatonin administration along with IL-2 and naltrexone in patients with untreatable metastatic melanoma increased Th-1 and suppressed Th-2 responses, a reportedly favorable result in anticancer treatment [108-111]. In the studies by Lissoni *et al.* it was found that advanced neoplasms resistant to IL-2 responded well to IL-2 therapy after the concomitant administration of melatonin [112-115]. Patients who received both IL-2 and melatonin exhibited a significantly higher number of lymphocytes, T lymphocytes, NK cells and CD4⁺ cells than those receiving IL-2 alone. A further study using IL-2 along with melatonin and cisplatin demonstrated that it was the most effective immunotherapeutic way for treating metastatic melanoma. In that study the combination of melatonin with IL-2 was proved to be successful after failure of a first line therapy with decarbazine and IFN- α . Melatonin not only suppressed tumor growth but also suppressed significantly the toxicity of chemotherapeutic drugs and potentiated their anticancer cytotoxicity [112-115].

In a study aiming to determine location and intensity of expression of MT₁ melatonin receptors and of Ki-67 proliferation-associated antigen in dermal melanoma, material from 48 cases of dermal melanoma, including 38 primary tumors and 10 metastatic lymph nodes was examined [116]. Expression of MT₁ receptor was more pronounced in primary tumors than in related metastatic lymph nodes. Depth of tumor infiltration demonstrated a moderate positive correlation with the intensity of MT₁ expression and a strongly positive correlation with the expression of Ki-67 antigen. In both primary tumors and metastatic lymph nodes, a weak correlation was found between the expression of MT₁ receptor and the expression of Ki-67 antigen [116].

Melatonin was effective in inhibiting cell proliferation of S-91 murine melanoma cells, under both *in vitro* and *in vivo* conditions [117]. Melatonin exerted its antiproliferative action by increasing the expression of MT₁ receptor and also

by increasing the activity of antioxidant enzymes. Early studies demonstrated that melatonin can act directly at the cellular level to inhibit the proliferation of PG 19 and B16BL6 mouse melanoma cells in culture [118]. The antiproliferative action of melatonin is dose-dependent [119]. With the highest melatonin concentration employed (19356 pg /cell) the cancer cells became undetectable at day 5 of treatment. The total elimination of cancer cells observed in this study was the first of this kind reported in the scientific literature.

The disruption of circadian rhythmicity becomes significant as a tumor progresses, whereas the incidence of cancer augments after disruption of the circadian system. In a study to test whether body temperature rhythms are impaired by tumor progression, and to what extent exogenous melatonin restricts tumor growth and restores circadian rhythmicity, C57 mice were subcutaneously inoculated with melanoma cells [120]. Animals were then submitted to 12:12 light-dark (LD) cycles or to continuous light (LL), with or without melatonin administration (2 mg/kg/day). Under LD light conditions, the body temperature rhythm exhibited a marked reduction and increased phase instability as the tumor progressed. Melatonin administration increased the body temperature rhythm amplitude and phase stability, reduced tumor weight and prevented intraperitoneal dissemination when administered in the subjective night [120].

The effect of melatonin on the growth of uveal melanoma cells has also been examined. Hu and his coworkers [121], by using cultured human uveal melanoma cells, found that melatonin (0.1-10 nM) inhibited the growth cells in a dose-dependent manner. Growth inhibition occurred at a concentration of 2 nM, the physiological levels found in aqueous humor. High affinity melatonin binding sites occurred in SK-Mel 28 human melanoma cell lines. In these cells use of luzindole, a blocker of MT₁ and MT₂ melatonin receptors reversed the anti-proliferative and melanogenic effects of melatonin [122]. In human melanoma cells SK-MEL-1, the antiproliferative effects of melatonin were associated with an alteration in the progression of the cell cycle and also with an increase in tyrosinase activity, a key regulatory enzyme of melanogenesis [123]. Antagonists for melatonin membrane receptors (luzindole and 4-phenyl-2-propionamidotetralin, 4-P-PDOT) and the general G-coupled receptor inhibitor, pertussis toxin, did not prevent the melatonin-induced cell growth arrest; this suggests a mechanism independent of G-coupled membrane receptors. The p38 mitogen-activated protein kinase signaling pathway seems to play a significant role in cell growth inhibition by melatonin [123].

Serum melatonin levels in patients with melanoma were higher than those of normal individuals [124]. Similarly, another study reported high serum melatonin levels in patients with choroidal melanoma; in this case melatonin levels decreased after enucleation by transpupillary thermotherapy [125]. The increase of serum melatonin levels seen in patients with choroidal melanoma was linked to the growth inhibitory effect melatonin on human melanoma cells as demonstrated under *in vitro* conditions [125]. It is likely that either intracellular melatonin levels are low in patients with melanoma or alternatively that the distribution of membrane MT₁ and MT₂ receptors themselves might be

deficient. Hence, as a compensatory mechanism these patients produce large amounts of melatonin which can be viewed as a mechanism for inhibiting cancerous growth.

MELATONIN IN BREAST CANCER

Melatonin is oncostatic and antiproliferative in breast cancer [126,127]. Studies using MCF-7 human breast cancer cells demonstrated that physiological concentrations of melatonin inhibit cell proliferation. As the melatonin's growth inhibitory effect was abolished by MT₁ receptor antagonism, the MT₁ receptors detectable in MCF-7 cells were identified as functional receptors responsible for transducing growth inhibitory effect of melatonin [128]. As the antiproliferative effect of melatonin is also a serum dependent phenomenon, the interaction of melatonin with a factor in the serum has been postulated for its antiproliferative action.

Melatonin not only blocks the mitogenic effects of estradiol but is also able to counteract the estradiol-induced invasiveness of MCF-7 cells [129]. *In vitro* experiments with the ER- positive MCF-7 human breast cancer cells demonstrated that melatonin at physiological concentrations (1 nM) inhibited the cell proliferation in the presence of serum or estradiol and increased the expression of p53 and p21WAF1 proteins, which modulate the length of cell cycle [130]. There is indication that melatonin could exert its antitumoral effects on hormone-dependent mammary tumors by down-regulating the sulfatase pathway of the tumoral tissue [131]. Since melatonin binds to calmodulin in a Ca²⁺ dependent fashion, calmodulin was implicated in the antiestrogenic effects of melatonin. Melatonin acts as a calmodulin antagonist inducing conformational changes of the ER α -CaM complex thus impairing binding of the ER α -CaM complex to DNA and thereby transcription [132]. This has been suggested as the mechanism by which melatonin exerts oncostatic and antiproliferative actions.

In recent years increased breast cancer risk in women associated with work at night-shifts has been attributed to the low melatonin levels following light-induced inhibition of melatonin synthesis [133-139]. The protective role of melatonin in mammary carcinogenesis was also suggested by studies in postmenopausal women with advanced breast cancer who have diminished urinary levels of melatonin as compared to controls [140]. The inhibitory action of melatonin on mammary carcinogenesis has been attributed to effect of melatonin on immune modulation [141]. Indeed, disturbances of immune mechanisms have been documented in experimental models of mammary cancer. For example, the absence of the cytosolic protein Nod1 in MCF-7 cells correlated with tumor growth, an increased sensitivity to estrogen induced cell proliferation, and a failure to undergo Nod1-dependent apoptosis [142].

IL-2 and chemotherapy are employed for treatment of metastatic breast cancer [143]. IL-2 is used to achieve an increased efficacy of increasing NK cells and cytolytic function and, in combination with IFN- α and chemotherapy, as an adjuvant treatment in high-risk breast cancer [144]. The link between melatonin and the immune system in cancer has been explored in phase II studies with melatonin

causing increase of some cytokines and amplification of objective responses to cytokine in patients [145].

A correlation between tumor size and the nocturnal amplitude of melatonin secretion was noted in some studies. Peak nocturnal amplitude of melatonin was reduced in 50% of patients with primary breast cancer and was inversely correlated with tumor size [146]. The nocturnal amplitude of the 6-sulfatoxymelatonin concentration was found lower in patients with primary breast cancer. The circadian rhythm of nocturnal melatonin production may represent a "regulatory signal" for the carcinogenic process; it may exert a "natural restraint" on tumor initiation, promotion, and/or progression [147,148].

MELATONIN IN OVARIAN, ENDOMETRIAL, AND OTHER CANCERS OF THE FEMALE REPRODUCTIVE TRACT

Low melatonin secretion has been reported in patients with endometrial cancer, but not in those with non-invasive ovarian cancer or squamous cervical cancer [149]. *In vitro*, an ovarian adenocarcinoma cell line (BG-1) exposed to melatonin (1-100 nM) showed a 20-25 % reduction in cell number [25]. In another study application of melatonin to ovarian carcinoma cell cultures revealed that three out of seven ovarian cell cultures were affected by melatonin in different ways melatonin [150]. Cells of one tumor were inhibited by 90% at 10 nM, while in another the growth inhibition was by 30 % at a concentration 0.1 – 1000 nM; a third specimen was stimulated up to 30% by 100 nM melatonin. The variability in the response was attributed to the presence of some unknown tumor condition likely to modify the melatonin response [150].

Melatonin did not exert antiproliferative effects on ovarian cancer cell lines at 0.001 nM - 1 μ M concentrations but enhanced the sensitivity to cisplatin in two ovarian cell lines [151]. Results were interpreted as indicating that melatonin may play a role in the control of telomerase activity and the suggestion was made that the resistance of ovarian cancer to cisplatin could be overcome by the administration of melatonin.

In ovarian cancer patients, IL-2 treatment has been employed [152]. For example, in the analysis of six studies of i.p. immunotherapy in ovarian cancer, 21 individual responses to IL-2 treatment were reported out of 69 patients showing a 22% of clinical efficacy [153]. Since melatonin increases the production of IL-2, the prospective therapeutic role of melatonin in cancer is that it may well act as a modulator of IL-2 and IFN- γ production by Th1 cells. Melatonin has the possibility of being used as a novel oncostatic adjuvant agent [154,155].

MELATONIN IN HEPATOCELLULAR CARCINOMA

Hepatocellular carcinoma is the cancer of the liver found after hepatitis B and hepatitis C infection, as well as in conditions associated with alcohol abuse [156]. Many immunotherapeutic procedures were employed for treating hepatocellular carcinoma, like the use of cytokines or transfer of autologous-activated lymphocytes. Intratumor injection of recombinant adenoviral vectors that induce the local

release of interleukin -12 has also been employed [157]. Improvement in overall recurrence-free survival was seen in 155 hepatocellular carcinoma patients after immunotherapy with IL-2 and α CD3 [158]. In another study carried out on stage III and IV inoperable patients, IL-2 administered along with IFN- γ and transarterial chemotherapy brought about tumor size reduction in 14 out of 20 patients [159].

Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line [160,161]. In 100 patients with inoperable advanced primary hepatocellular carcinoma, transcatheter arterial chemoembolization (TACE) was used alone or associated with melatonin [162]. The effectiveness rate of TACE or TACE + melatonin was 16 % and 28 %, respectively. The 0.5, 1 and 2 year survival rate in the TACE group was 82 %, 54 %, and 26 % respectively, while in the TACE + melatonin it was 100 %, 68 % and 40 %, respectively. IL-2 levels were found elevated in all these patients. The protective and treatment effect of TACE plus melatonin on liver function was attributed to enhancement of immunological function in patients [162].

MELATONIN IN COLORECTAL CARCINOMA

Epidemiological studies of nurses engaged in night-shift work indicated an increased incidence of colorectal cancer, a finding interpreted as supporting the cancer-promoting effect of melatonin inhibition by environmental light [136,163]. Indeed, many *in vitro* and *in vivo* studies have shown that melatonin exerts antiproliferative effects on intestinal cancer. In a study on CT-26 a murine colon carcinoma-derived cell line, melatonin inhibited growth in a dose-dependent manner [164]. A statistically significant correlation was found between the decrease in DNA synthesis and the doses of melatonin used. The growth inhibitory effect found was 22% (1 nM melatonin), 25 % (2 mM melatonin) and 47 % (3 mM melatonin) [164]. High melatonin binding sites were demonstrated in human colonic mucosa and a melatonin concentration of $467 \pm \text{pg/g}$ of wet tissue of human colon has been reported [165]. The oncostatic action of melatonin appears to depend on both MT_2 and nuclear RZR/ ROR receptors [166]. Luzindole (a MT_1/MT_2 antagonist) but not 4-P-PDOT (a specific MT_2 antagonist) diminishes the inhibitory effect of melatonin on murine colon 38 cancer cell growth *in vitro* [167].

The inhibitory effect of exogenous melatonin on colon oncogenesis was investigated using the azoxymethane/dextran sodium sulfate rat model [168]. At week 20, the development of colonic adenocarcinoma was significantly inhibited by the administration with melatonin in a dose-dependent manner. Melatonin exposure decreased mitotic and apoptotic indices in the colonic adenocarcinomas and lowered the immunohistochemical expression of nuclear factor κ B, TNF- α , IL-1 β and STAT3 in the epithelial malignancies. These results may indicate the beneficial effects of melatonin on colitis-related colon carcinogenesis and a potential application for inhibiting colorectal cancer development in the inflamed colon.

Early studies on the effects of melatonin in colorectal carcinoma were based upon the immunoneuroendocrine and synergistic relationship between melatonin and IL-2 [169].

In a study on 24 patients with advanced cell tumors who did not respond to previous chemotherapies (non-small cell lung cancer, 9 patients; colorectal cancer, 7 patients; gastric cancer, 3 patients; breast cancer, 2 patients; cancer of pancreas, 1 patient; hepatocarcinoma, 1 patient; unknown tumor, 1 patient), IL-2 plus melatonin was given. Melatonin was administered starting 7 days before IL-2 injection. While progress was reported in 6/24 patients, stability was reported in 14/24 patients. IL-2 in combination with melatonin seemed useful to control tumor growth in patients with advanced neoplasms [170]. In another study on 35 patients with advanced neoplasms of the digestive tract, immunotherapy with a low-dose of IL-2 plus melatonin was a well-tolerated and effective therapy. Complete response was obtained in patients with gastric carcinoma and hepatocarcinoma. The overall response rate was 8/35 (23%) [171]. Similarly, in another study a low subcutaneous dose of IL-2 plus melatonin was found to be a second - line therapy for tumor regression and for prolonging survival of patients with metastatic colorectal cancer [172].

Measurements of melatonin levels in patients with colorectal patients and controls demonstrated a higher nocturnal concentration in patients [173]. Daytime melatonin concentrations in gut tissue of colorectal carcinoma patients was found to be $317 \pm 87.8 \text{ pg/g}$, nearly 10 times higher than the day time levels in circulation. An increased level of melatonin in the gut has been found after surgery and it was suggested that they play a protective role against the development of colorectal cancer [173].

The interrelationship between melatonin and immune function was studied in patients with advanced GI cancer (42 patients with colorectal, gastric and pancreatic cancer) [174]. The circadian rhythm of melatonin was altered with peak melatonin level reaching at 0800 - 0900 h, with a 5-7 h-delay respecting average peak time in healthy humans. The rhythm in TNF- α and soluble TNF- α receptors (type I and type II) also indicated the existence of complex self-regulatory mechanisms between the neuroendocrine system and the cytokine network in those patients [174]. Suppression of nocturnal melatonin rise in mothers with mastitis was highly correlated with increased TNF- α secretion from immunocompetent cells phagocytes in calostrum [175].

Besides interacting with cytokines, melatonin induces direct cell death of cancer cells by apoptosis. In a study on HT-29 human colon cancer cells, melatonin potentiated flavone-induced apoptosis [176]. The role of melatonin as pro-apoptotic agent is a new field of investigation. The pro-apoptotic action of melatonin has been documented not only in colon cancer cells [177] but also in breast cancer [178]. The mechanisms underlying the pro-apoptotic action of melatonin are discussed below when dealing with melatonin effects in prostate cancer. The finding that melatonin induces apoptosis uniformly in all cancer cells may have important clinical significance. It could involve free radical scavenging properties and other intracellular pathways. Indeed, the antioxidant and anti-inflammatory actions of melatonin, counteracting the oxidative status and reducing the production of nitric oxide by cultured HT-29 cells seem to be directly involved in its oncostatic properties [179].

MELATONIN IN PROSTATE CANCER

There are several postulated mechanisms by which melatonin may inhibit prostate cancer. The inhibitory effect of melatonin on androgen-sensitive prostate tumors was first demonstrated by using the transplantable Dunning (R3327) prostatic tumor in Copenhagen Fisher male rats [180]. In these animals late afternoon injections of melatonin significantly inhibited the growth of androgen-sensitive prostatic tumors. The mechanism through which melatonin induces tumor suppression in prostate cells was then studied. Both melatonin and its analog 2-iodomelatonin attenuate epidermal growth factor-stimulated cyclin D1 levels and cell proliferation in human LNCaP prostate cancer cells [181]. Melatonin had no effect on androgen-insensitive prostate cancer cell proliferation (DU145 and PC-3 cells) in which the MT₁ receptor mediated signal transduction was defective [182]. Melatonin inhibited the proliferation of hormone-dependent LNCaP prostate cancer cells partly through MT₁ receptor activation both *in vitro* and *in vivo* as shown in the nude mice xenograft model [181]. Melatonin has been shown to reduce prostate cancer cell number and stop cell cycle progression in both androgen-dependent LNCaP cells and androgen independent PC3 cells. These effects were not mediated by membrane melatonin receptors and did not involve PKA activation [183].

A number of studies have shown that melatonin has antiangiogenic properties and this also is said to be one of the major actions through which it exerts its anti-tumorigenic activity. The mechanism of melatonin's antiangiogenic effect is still under investigation. A recent study has shown that it relays on melatonin action on the expression of hypoxia-inducible factor-1(HIF-1) [184]. At pharmacological concentrations melatonin inhibited expression of HIF-1 alpha protein under both normoxic and hypoxic conditions in DU 145, PC-3 and LNCaP prostate cancer cells without affecting HIF-1 alpha mRNA levels. The suppression of HIF-1 alpha expression by melatonin correlated with dephosphorylation of p70S6K and its direct target RPS6, a pathway that regulates HIF-1 alpha expression at the translational level suggesting that melatonin exerts its oncostatic activity by inhibiting HIF-1 protein translation in prostate cancer cells [184].

Induction of cancer cell apoptosis is also an important strategy of anticancer therapy. While inhibiting the growth of prostate cancer cells (LNCaP) melatonin promoted apoptosis *via* mitogen-activated protein kinases [185]. Both early and late stages of apoptosis were promoted by melatonin. Melatonin induced apoptosis in these cancerous cells *via* JNK (c-JUN N-terminal kinase) and p-38 dependent processes but not through ERK-dependent processes [185].

The molecular mechanisms of melatonin action in prostate cancer were further studied recently by analyzing the effect of melatonin on Sirt1 (a NAD⁺-dependent histone deacetylase) that is found overexpressed in prostate cancer (PCa) cells. Melatonin significantly inhibited Sirt1 protein and activity and this inhibition was accompanied by a significant decrease in the proliferative potential of PCa cells, suggesting that Sirt1 is a direct target of melatonin's anti proliferative action [186]. In the same study authors used mice with transgenic prostatic adenocarcinoma for

evaluating the anti-cancer effects of melatonin. The oral administration of melatonin significantly inhibited tumorigenesis and decreased a number of proliferation markers including Sirt1 in TRAMP prostate [186].

Melatonin has also been shown to exert its antiproliferative activity in prostate cancer cells *via* resynchronization of deregulated core clockwork [187]. Melatonin administration resulted in an increase in *Per2* and *Clock* and reduction in *Bmal1* in human prostate cancer cells. In addition melatonin treatment also caused resynchronization of oscillatory circadian genes (*Dbp* and *Per2*). This study supports that alterations of circadian rhythms is one of the predisposing factor for development of prostate cancer. Melatonin being a chronobiotic can exert some antiproliferative effects through its action on core set of genes involved in the regulation of circadian rhythms.

The effect of melatonin on melatonin receptor expression and levels of prostate serum antigen (PSA) was evaluated in prostate cancer patients by examining cancer tissue biopsy and blood serum [181]. MT₁ melatonin receptors were expressed in prostate tumors. Based on serum PSA measurements, it was shown that administration of melatonin (5 mg/day at 20:00 h) induced stabilization of prostate cancer disease, thus suggesting that melatonin had oncostatic action in prostate cancer patients [181]. A rapid analytical method has recently been developed for monitoring intracellular melatonin concentrations by in normal (PNT1A) and cancerous prostate cells [188].

CURRENT & FUTURE DEVELOPMENTS

Melatonin has been demonstrated to inhibit tumor development under both *in vivo* and *in vitro* conditions. There are several mechanisms by which melatonin can exert its oncostatic actions: (a) by its direct pro-apoptotic, gene-mediated, actions on tumor cells; (b) by its antioxidant actions; (d) by reducing the uptake of key factors for tumor growth and tumor growth signaling molecules (e.g., linoleic acid); (d) by enhancing immune mechanisms in body; (e) through antiangiogenic effects.

The fact that there is an increased incidence of neoplastic diseases at an old age, concomitant with the age-associated decline in immune functions of the body, have prompted many investigations aiming to identify agents that could enhance immune function. Of the various substances examined, melatonin received wide attention as it enhances immune function effectively in both animals and humans. Alterations in circadian rhythms occurring with aging are also a risk factor for cancer development. Melatonin treatment has been shown to resynchronize oscillatory circadian rhythm genes in cancer cells and thereby can act as a good therapeutic agent for the management of age-related malignancies. Altered melatonin levels (mainly decreased levels) have been reported in patients suffering from melanoma, breast cancer, and colorectal cancer, among other. Melatonin suppresses growth of melanoma, breast cancer, ovarian cancer and colorectal, prostate and other cancers by interacting directly with tumor cells through MT₁ and MT₂ melatonin receptors; melatonin stimulates NK cell activity, regulatory Th cell activity and enhances the release of cytokines like IL-2 and IFN- γ from T lymphocytes.

Melatonin acts also by activating various pathways involved in apoptosis and has been identified as a novel Sirt1 inhibitor in prostate cancer.

Undoubtedly, melatonin has the potentiality of being used as an effect therapeutic agent for treating breast cancer, prostate cancer, colorectal cancer, melanoma and various other types of cancer. Based on findings observed in animals, phase II clinical trials are being undertaken wherein the administration of melatonin along with IL-2 is found beneficial in treating patients suffering from various neoplastic diseases like melanoma or colorectal cancer. Melatonin has the potentiality to become a useful oncostatic drug [189].

PATENT SELECTION

The following recent patents are considered by the authors to be relevant in the field of melatonin and cancer. It must be noted that melatonin, as a natural product, cannot be patented itself but through its different uses.

[190] This invention is directed to combinations of compounds useful in the treatment and prevention of cancer and inflammatory conditions or diseases.

[191] The invention explains use of glycosylasparaginase polypeptide for treatment cancers.

[192] This invention relates to the use of at least one of melatonin, a melatonin analogue, or a pharmaceutically acceptable salt thereof in the treatment of certain cancers, in particular metastatic colorectal cancer and metastatic breast cancer.

[193] This invention relates to methods and compositions for treating cancer, the methods including the step administering, either sequentially or simultaneously, several compounds and melatonin

[194] This invention relates to methods for preventing the development of cancer or neurodegenerative diseases by administering melatonin or N-acetylcysteine alone or in combination.

[195] This invention proposed melatonin as a useful agent to prevent skin against damage induced by ultraviolet radiation.

[196] This invention proposed a method of maintaining circadian rhythm of a subject comprising selectively blocking of retinal exposure of the subject to light having a wavelengths that do not inhibit melatonin synthesis at night, thus preventing the consequences of night work, in particular those of tumor growth.

[197] This invention describes a light emitting diode lamp free of melatonin-suppressing radiation for preventing the consequences of night work in particular those of tumor growth.

ACKNOWLEDGEMENTS

D.P.C. is a Research Career Awardee from the Argentine National Research Council (CONICET), Argentina and Professor Emeritus, University of Buenos Aires.

CONFLICT OF INTEREST

S.R. Pandi-Perumal is a stockholder and the President and Chief Executive Officer of Somnogen Inc., a New York Corporation. He declared no competing interests that might be perceived to influence the content of this article. All remaining authors declare that they have no proprietary, financial, professional, nor any other personal interest of any kind in any product or services and/or company that could be construed or considered to be a potential conflict of interest that might have influenced the views expressed in this manuscript.

REFERENCES

- [1] Paredes SD, Korkmaz A, Manchester LC, Tan DX, Reiter RJ. Phytomelatonin: a review. *J Exp Bot* 2009; 60: 57-69.
- [2] Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal? *FEBS J* 2006; 273: 2813-38.
- [3] Chen G, Huo Y, Tan DX, Liang Z, Zhang W, Zhang Y. Melatonin in Chinese medicinal herbs. *Life Sci* 2003; 73: 19-26.
- [4] Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, et al. The role of oxidative stress in chemical carcinogenesis. *Environ Health Perspect* 1998; 106 Suppl 1: 289-95.
- [5] Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. *Endocr J* 1993; 1: 57-60.
- [6] Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. *Endocrine* 2005; 27: 179-88.
- [7] Miller SC, Pandi-Perumal SR, Esquifino AI, Cardinali DP, Maestroni GJ. The role of melatonin in immuno-enhancement: potential application in cancer. *Int J Exp Pathol* 2006; 87: 81-7.
- [8] Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant, geroprotector and anticarcinogen. *Biochim Biophys Acta* 2006; 1757: 573-89.
- [9] Jung B, Ahmad N. Melatonin in cancer management: progress and promise. *Cancer Res* 2006; 66: 9789-93.
- [10] Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Esquifino AI, Cardinali DP, et al. Melatonin, environmental light, and breast cancer. *Breast Cancer Res Treat* 2008; 183: 339-50.
- [11] Reiter RJ. Melatonin, active oxygen species and neurological damage. *Drug News Perspect* 1998; 11: 291-6.
- [12] Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. *Neurotox Res* 2005; 7: 293-318.
- [13] Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP. Melatonin and sleep in aging population. *Exp Gerontol* 2005; 40: 911-25.
- [14] Arlt W, Hewison M. Hormones and immune function: implications of aging. *Aging Cell* 2004; 3: 209-16.
- [15] Maestroni GJ. The immunotherapeutic potential of melatonin. *Expert Opin Investig Drugs* 2001; 10: 467-76.
- [16] Carrillo-Vico A, Reiter RJ, Lardone PJ, Herrera JL, Fernandez-Montesinos R, Guerrero JM, et al. The modulatory role of melatonin on immune responsiveness. *Curr Opin Investig Drugs* 2006; 7: 423-31.
- [17] Guerrero JM, Reiter RJ. Melatonin-immune system relationships. *Curr Top Med Chem* 2002; 2: 167-79.
- [18] Maestroni GJ, Conti A, Pierpaoli W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. *Ann N Y Acad Sci* 1988; 521: 140-8.
- [19] Maestroni GJ, Conti A. The pineal neurohormone melatonin stimulates activated CD4⁺, Thy-1⁺ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties. *J Neuroimmunol* 1990; 28: 167-76.
- [20] Lissoni P, Brivio O, Brivio F, Barni S, Tancini G, Crippa D, et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. *J Pineal Res* 1996; 21: 239-42.

- [21] Martins E Jr, Fernandes LC, Bartol I, Cipolla-Neto J, Costa Rosa LF. The effect of melatonin chronic treatment upon macrophage and lymphocyte metabolism and function in Walker-256 tumour-bearing rats. *J Neuroimmunol* 1998; 82: 81-9.
- [22] Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. *Cancer Res* 1988; 48: 6121-6.
- [23] Cos S, Sanchez-Barcelo EJ. Melatonin and mammary pathological growth. *Front Neuroendocrinol* 2000; 21: 133-70.
- [24] Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. *Integrat Cancer Ther* 2008; 7: 189-203.
- [25] Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC, Murphy E. The oncostatic action of melatonin in an ovarian carcinoma cell line. *J Pineal Res* 1999; 26: 129-36.
- [26] Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. *J Pineal Res* 2000; 28: 227-33.
- [27] Hu DN, Roberts JE. Melatonin inhibits growth of cultured human uveal melanoma cells. *Melanoma Res* 1997; 7: 27-31.
- [28] Gilad E, Laufer M, Matzkin H, Zisapel N. Melatonin receptors in PC3 human prostate tumor cells. *J Pineal Res* 1999; 26: 211-20.
- [29] Anisimov VN, Popovich IG, Zabezhinski MA. Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. *Carcinogenesis* 1997; 18: 1549-53.
- [30] Subramanian P, Mirunalini S, Dakshayani KB, Pandi-Perumal SR, Trakht I, Cardinali DP. Prevention by melatonin of hepatocarcinogenesis in rats injected with N-nitrosodiethylamine. *J Pineal Res* 2007; 43: 305-12.
- [31] Axelrod J. The pineal gland: a neurochemical transducer. *Science* 1974; 184: 1341-8.
- [32] Moore RY. Circadian rhythms: basic neurobiology and clinical applications. *Annu Rev Med* 1997; 48: 253-66.
- [33] Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. *Science* 2002; 295: 1070-3.
- [34] Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, Gerner E, *et al.* Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. *J Neurosci* 2001; 21: 6405-12.
- [35] Klein DC. The 2004 Aschoff/Pittendrigh lecture: Theory of the origin of the pineal gland--a tale of conflict and resolution. *J Biol Rhythms* 2004; 19: 264-79.
- [36] Cardinali DP, Lynch HJ, Wurtman RJ. Binding of melatonin to human and rat plasma proteins. *Endocrinology* 1972; 91: 1213-8.
- [37] Cardinali DP, Pévet P. Basic aspects of melatonin action. *Sleep Med Rev* 1998; 2: 175-90.
- [38] Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. *Sleep Med Rev* 2005; 9: 11-24.
- [39] Tan DX, Manchester LC, Reiter RJ, Plummer BF, Hardies LJ, Weintraub ST, *et al.* A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of *in vivo* hydroxyl radical generation. *Biochem Biophys Res Commun* 1998; 253: 614-20.
- [40] Hirata F, Hayaishi O, Tokuyama T, Seno S. *In vitro* and *in vivo* formation of two new metabolites of melatonin. *J Biol Chem* 1974; 249: 1311-3.
- [41] Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. *J Pineal Res* 2009; 47: 109-16.
- [42] Leon J, Acuña-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ. Melatonin and mitochondrial function. *Life Sci* 2004; 75: 765-90.
- [43] Dubocovich ML, Markowska M. Functional MT₁ and MT₂ melatonin receptors in mammals. *Endocrine* 2005; 27: 101-10.
- [44] Dubocovich ML, Delagrangre P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. *Pharmacol Rev* 2010; 62: 343-80.
- [45] Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, *et al.* Identification of the melatonin-binding site MT₃ as the quinone reductase 2. *J Biol Chem* 2000; 275: 31311-7.
- [46] Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, *et al.* Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. *J Biol Chem* 2002; 277: 21522-8.
- [47] Daulat AM, Maurice P, Froment C, Guillaume JL, Broussard C, Monsarrat B, *et al.* Purification and identification of G protein-coupled receptor protein complexes under native conditions. *Mol Cell Proteomics* 2007;
- [48] Reppert SM, Weaver DR, Ebisawa T, Mahle CD, Kolakowski LF, Jr. Cloning of a melatonin-related receptor from human pituitary. *FEBS Lett* 1996; 386: 219-24.
- [49] Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrangre P, *et al.* The orphan GPR50 receptor specifically inhibits MT₁ melatonin receptor function through heterodimerization. *EMBO J* 2006; 25: 3012-23.
- [50] Levoye A, Jockers R, Ayoub MA, Delagrangre P, Savaskan E, Guillaume JL. Are G protein-coupled receptor heterodimers of physiological relevance?--Focus on melatonin receptors. *Chronobiol Int* 2006; 23: 419-26.
- [51] Benitez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. *J Pineal Res* 2006; 40: 1-9.
- [52] Cardinali DP, Freire F. Melatonin effects on brain. Interaction with microtubule protein, inhibition of fast axoplasmic flow and induction of crystalloid and tubular formations in the hypothalamus. *Mol Cell Endocrinol* 1975; 2: 317-30.
- [53] Wiesenberg I, Missbach M, Carlberg C. The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling. *Restor Neurol Neurosci* 1998; 12: 143-50.
- [54] Slominski A, Fischer TW, Zmijewski MA, Wortsman J, Semak I, Zbytek B, *et al.* On the role of melatonin in skin physiology and pathology. *Endocrine* 2005; 27: 137-48.
- [55] Roberts JE, Wiechmann AF, Hu DN. Melatonin receptors in human uveal melanocytes and melanoma cells. *J Pineal Res* 2000; 28: 165-71.
- [56] Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. *Curr Top Med Chem* 2002; 2: 113-32.
- [57] Carlberg C. Gene regulation by melatonin. *Ann N Y Acad Sci* 2000; 917: 387-96.
- [58] Lincoln G, Messenger S, Andersson H, Hazlerigg D. Temporal expression of seven clock genes in the suprachiasmatic nucleus and the pars tuberalis of the sheep: evidence for an internal coincidence timer. *Proc Natl Acad Sci U S A* 2002; 99: 13890-5.
- [59] Wiechmann AF. Regulation of gene expression by melatonin: a microarray survey of the rat retina. *J Pineal Res* 2002; 33: 178-85.
- [60] Prunet-Marcassus B, Ambid L, Viguerie-Bascands N, Penicaud L, Casteilla L. Evidence for a direct effect of melatonin on mitochondrial genome expression of Siberian hamster brown adipocytes. *J Pineal Res* 2001; 30: 108-15.
- [61] Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Lofgren S, *et al.* An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. *J Gerontol A Biol Sci Med Sci* 2005; 60: 556-65.
- [62] Tarazona R, Solana R, Ouyang Q, Pawelec G. Basic biology and clinical impact of immunosenescence. *Exp Gerontol* 2002; 37: 183-9.
- [63] Pawelec G, Ouyang Q, Colonna-Romano G, Candore G, Lio D, Caruso C. Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes'. *Trends Immunol* 2002; 23: 330-2.
- [64] Pawelec G, Akbar A, Caruso C, Effros R, Grubeck-Loebenstien B, Wikby A. Is immunosenescence infectious? *Trends Immunol* 2004; 25: 406-10.
- [65] Borrego F, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B, *et al.* NK phenotypic markers and IL2 response in NK cells from elderly people. *Exp Gerontol* 1999; 34: 253-65.
- [66] Miyaji C, Watanabe H, Toma H, Akisaka M, Tomiyama K, Sato Y, *et al.* Functional alteration of granulocytes, NK cells, and natural killer T cells in centenarians. *Hum Immunol* 2000; 61: 908-16.
- [67] Srinivasan V, Maestroni G, Cardinali D, Esquifino A, Perumal SP, Miller S. Melatonin, immune function and aging. *Immun Ageing* 2005; 2: 17

- [68] Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. *J Exp Med* 2002; 196: 129-34.
- [69] Stanta G, Campagner L, Cavallieri F, Giarelli L. Cancer of the oldest old. What we have learned from autopsy studies. *Clin Geriatr Med* 1997; 13: 55-68.
- [70] Kerr D, Krishnan C, Pucak ML, Carmen J. The immune system and neuropsychiatric diseases. *Int Rev Psychiatry* 2005; 17: 443-9.
- [71] Segerstrom SC. Optimism and immunity: do positive thoughts always lead to positive effects? *Brain Behav Immun* 2005; 19: 195-200.
- [72] Burnet M. Somatic mutation and chronic disease. *Br Med J* 1965; 5431: 338-42.
- [73] Cardinali DP, Esquifino AI, Srinivasan V, Pandi-Perumal SR. Melatonin and the immune system in aging. *Neuroimmunomodulation* 2008; 15: 272-8.
- [74] Skwarlo-Sonta K. Melatonin in immunity: comparative aspects. *Neuro Endocrinol Lett* 2002; 23 Suppl 1: 61-6.
- [75] Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S, Reiter RJ, et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. *FASEB J* 2004; 18: 537-9.
- [76] Lardone PJ, Carrillo-Vico A, Naranjo MC, De Felipe B, Vallejo A, Karasek M, et al. Melatonin synthesized by Jurkat human leukemic T cell line is implicated in IL-2 production. *J Cell Physiol* 2006; 206: 273-9.
- [77] Naranjo MC, Guerrero JM, Rubio A, Lardone PJ, Carrillo-Vico A, Carrascosa-Salmoral MP, et al. Melatonin biosynthesis in the thymus of humans and rats. *Cell Mol Life Sci* 2007; 64: 781-90.
- [78] Ueno-Towatari T, Norimatsu K, Blazejczyk K, Tokura H, Morita T. Seasonal variations of melatonin secretion in young females under natural and artificial light conditions in Fukuoka, Japan. *J Physiol Anthropol* 2007; 26: 209-15.
- [79] Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinali DP, Maestroni GJM. Immunomodulation by melatonin: Its significance for seasonally-occurring diseases. *Neuroimmunomodulation* 2008; 15: 93-101.
- [80] Nelson RJ. Seasonal immune function and sickness responses. *Trends Immunol* 2004; 25: 187-92.
- [81] Nelson RJ, Drazen DL. Melatonin mediates seasonal changes in immune function. *Ann N Y Acad Sci* 2000; 917: 404-15.
- [82] Garcia-Maurino S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. *J Pineal Res* 2000; 29: 129-37.
- [83] Currier NL, Sun LZ, Miller SC. Exogenous melatonin: quantitative enhancement *in vivo* of cells mediating non-specific immunity. *J Neuroimmunol* 2000; 104: 101-8.
- [84] Maestroni GJ, Covacci V, Conti A. Hematopoietic rescue *via* T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. *Cancer Res* 1994; 54: 2429-32.
- [85] Maestroni GJ, Conti A, Lissoni P. Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin *via* endogenous interleukin 4. *Cancer Res* 1994; 54: 4740-3.
- [86] Angeli A, Gatti G, Sartori ML, Ponte D, Carignola R. Effect of exogenous melatonin on human natural killer (NK) cell activity. An approach to the immunomodulatory role of the pineal gland. In: Gupta D, Attanasio A, Reiter RJ, Eds., Tubingen: Brain Research Promotion, 1988: 145-56.
- [87] Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-El-Idrissi M, Sanchez-Margalet V, Goberna R, et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4⁺ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. *J Immunol* 1997; 159: 574-81.
- [88] Garcia-Maurino S, Pozo D, Carrillo-Vico A, Calvo JR, Guerrero JM. Melatonin activates Th1 lymphocytes by increasing IL-12 production. *Life Sci* 1999; 65: 2143-50.
- [89] Ossendorp F, Toes RE, Offringa R, van der Burg SH, Melief CJ. Importance of CD4⁺ T helper cell responses in tumor immunity. *Immunol Lett* 2000; 74: 75-9.
- [90] Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. *Cancer Immunol Immunother* 2005; 54: 721-8.
- [91] Castrillon P, Esquifino AI, Varas A, Zapata A, Cutrera RA, Cardinali DP. Effect of melatonin treatment on 24-hour variations in responses to mitogens and lymphocyte subset populations in rat submaxillary lymph nodes. *J Neuroendocrinol* 2000; 12: 758-65.
- [92] Raghavendra V, Singh V, Kulkarni SK, Agrewala JN. Melatonin enhances Th2 cell mediated immune responses: lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists. *Mol Cell Biochem* 2001; 221: 57-62.
- [93] Fernandes PA, Cecon E, Markus RP, Ferreira ZS. Effect of TNF-alpha on the melatonin synthetic pathway in the rat pineal gland: basis for a 'feedback' of the immune response on circadian timing. *J Pineal Res* 2006; 41: 344-50.
- [94] Markus RP, Ferreira ZS, Fernandes PA, Cecon E. The immune-pineal axis: a shuttle between endocrine and paracrine melatonin sources. *Neuroimmunomodulation* 2007; 14: 126-33.
- [95] Rizo H, Becker T, Holland EA. Cell cycle regulation in the melanocytes. In: Thompson JF, Morton DL, Kroon BB, Eds., Textbook of Melanoma. London: Martin Dunitz, 2004: 13-24.
- [96] Halliday GM. Skin immunity and melanoma development. In: Thompson JF, Morton DL, Kroon BB, Eds., Textbook of Melanoma. London: Martin Dunitz, 2004: 25-42.
- [97] Pandolfino MC, Viret C, Gervois N, Guilloux Y, Davodeau F, Diez E, et al. Specificity, T cell receptor diversity and activation requirements of CD4⁺ and CD8⁺ clones derived from human melanoma-infiltrating lymphocytes. *Eur J Immunol* 1992; 22: 1795-802.
- [98] Donawho CK, Muller HK, Bucana CD, Kripke ML. Enhanced growth of murine melanoma in ultraviolet-irradiated skin is associated with local inhibition of immune effector mechanisms. *J Immunol* 1996; 157: 781-6.
- [99] Fischer TW, Sweatman TW, Semak I, Sayre RM, Wortsman J, Slominski A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. *FASEB J* 2006; 20: 1564-6.
- [100] Kanikkannan N, Jackson T, Shaik MS, Singh M. Evaluation of skin sensitization potential of melatonin and nimesulide by murine local lymph node assay. *Eur J Pharm Sci* 2001; 14: 217-20.
- [101] Slominski A, Wortsman J, Tobin DJ. The cutaneous serotonergic/melatoninergic system: securing a place under the sun. *FASEB J* 2005; 19: 176-94.
- [102] Kim BC, Shon BS, Ryoo YW, Kim SP, Lee KS. Melatonin reduces X-ray irradiation-induced oxidative damages in cultured human skin fibroblasts. *J Dermatol Sci* 2001; 26: 194-200.
- [103] Bartsch H, Bartsch C, Noteborn HP, Flehmig B, Ebels I, Salemink CA. Growth-inhibiting effect of crude pineal extracts on human melanoma cells *in vitro* is different from that of known synthetic pineal substances. *J Neural Transm* 1987; 69: 299-311.
- [104] Oh HJ, Oh YK, Kim CK. Effects of vehicles and enhancers on transdermal delivery of melatonin. *Int J Pharm* 2001; 212: 63-71.
- [105] Lissoni P, Tisi E, Brivio F, Ardizzoia A, Crispino S, Barni S, et al. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin. *J Biol Regul Homeost Agents* 1991; 5: 154-6.
- [106] Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, et al. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin. *J Biol Regul Homeost Agents* 1993; 7: 121-5.
- [107] Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky W, Mecke D. The Pineal Gland and Cancer: Neuroimmunoendocrine Mechanisms in Malignancy. Berlin: Springer 2000.
- [108] Gonzalez R, Sanchez A, Ferguson JA, Balmer C, Daniel C, Cohn A, et al. Melatonin therapy of advanced human malignant melanoma. *Melanoma Res* 1991; 1: 237-43.
- [109] Lissoni P, Barni S, Tancini G, Rovelli F, Ardizzoia A, Conti A, et al. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients. *Oncology* 1993; 50: 399-402.
- [110] Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G, et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with

- cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. *Tumori* 1994; 80: 464-7.
- [111] Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, *et al.* A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha. *In Vivo* 2002; 16: 93-6.
- [112] Brivio F, Fumagalli L, Fumagalli G, Pescia S, Brivio R, Di Fede G, *et al.* Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression. *In Vivo* 2010; 24: 239-41.
- [113] Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. *In Vivo* 2008; 22: 397-400.
- [114] Lissoni P, Brivio F, Fumagalli L, Messina G, Vigore L, Parolini D, *et al.* Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. *Anticancer Res* 2008; 28: 1377-81.
- [115] Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. *Pathol Biol (Paris)* 2007; 55: 201-4.
- [116] Danielczyk K, Dziegiel P. The expression of MT₁ melatonin receptor and Ki-67 antigen in melanoma malignum. *Anticancer Res* 2009; 29: 3887-95.
- [117] Kadekaro AL, Andrade LN, Floeter-Winter LM, Rollag MD, Virador V, Vieira W, *et al.* MT₁ melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. *J Pineal Res* 2004; 36: 204-11.
- [118] Cos S, Garcia-Bolado A, Sanchez-Barcelo EJ. Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19). *Melanoma Res* 2001; 11: 197-201.
- [119] Yerneni LK, Jayaraman S. Pharmacological action of high doses of melatonin on B16 murine melanoma cells depends on cell number at time of exposure. *Melanoma Res* 2003; 13: 113-7.
- [120] Otalora BB, Madrid JA, Alvarez N, Vicente V, Rol MA. Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice. *J Pineal Res* 2008; 44: 307-15.
- [121] Hu DN, McCormick SA, Roberts JE. Effects of melatonin, its precursors and derivatives on the growth of cultured human uveal melanoma cells. *Melanoma Res* 1998; 8: 205-10.
- [122] Souza AV, Visconti MA, Castrucci AM. Melatonin biological activity and binding sites in human melanoma cells. *J Pineal Res* 2003; 34: 242-8.
- [123] Cabrera J, Negrin G, Estevez F, Loro J, Reiter RJ, Quintana J. Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. *J Pineal Res* 2010;
- [124] Kerenyi NA, Pandula E, Feuer GM. Oncostatic effects of the pineal gland. *Drug Metabol Drug Interact* 1990; 8: 313-9.
- [125] Kiratli H, Gedik S, Us D, Bilgic S. Serum melatonin levels following enucleation and transpupillary thermotherapy in patients with choroidal melanoma. *Clin Experiment Ophthalmol* 2003; 31: 505-8.
- [126] Blask DE, Hill SM. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. *J Neural Transm Suppl* 1986; 21: 433-49.
- [127] Hill SM, Frasca T, Xiang S, Yuan L, Duplessis T, Mao L. Molecular mechanisms of melatonin anticancer effects. *Integr Cancer Ther* 2009; 8: 337-46.
- [128] Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L, *et al.* Involvement of the mt1 melatonin receptor in human breast cancer. *Cancer Lett* 2002; 179: 141-50.
- [129] Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. *Cancer Res* 1998; 58: 4383-90.
- [130] Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells *in vitro*. *Life Sci* 1999; 65: 415-20.
- [131] Gonzalez A, Alvarez-Garcia V, Martinez-Campa C, Mediavilla MD, Alonso-Gonzalez C, Sanchez-Barcelo EJ, *et al.* *In vivo* inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin. *Curr Cancer Drug Targets* 2010; 10: 279-86.
- [132] del Rio B, Garcia Pedrero JM, Martinez-Campa C, Zuazua P, Lazo PS, Ramos S. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha *via* calmodulin. *J Biol Chem* 2004; 279: 38294-302.
- [133] Dopfel RP, Schulmeister K, Schernhammer ES. Nutritional and lifestyle correlates of the cancer-protective hormone melatonin. *Cancer Detect Prev* 2007; 31: 140-8.
- [134] Flynn-Evans EE, Stevens RG, Tabandeh H, Schernhammer ES, Lockley SW. Total visual blindness is protective against breast cancer. *Cancer Causes Control* 2009;
- [135] Schernhammer E, Chen H, Ritz B. Circulating melatonin levels: possible link between Parkinson's disease and cancer risk? *Cancer Causes Control* 2006; 17: 577-82.
- [136] Schernhammer ES, Feskanich D, Niu C, Dopfel R, Holmes MD, Hankinson SE. Dietary correlates of urinary 6-sulfatoxymelatonin concentrations in the Nurses' Health Study cohorts2. *Am J Clin Nutr* 2009;
- [137] Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. *Cancer Res* 2007; 67: 10618-22.
- [138] Stevens RG. Artificial lighting in the industrialized world: circadian disruption and breast cancer. *Cancer Causes Control* 2006; 17: 501-7.
- [139] Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturilli E, *et al.* Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. *Cancer Epidemiol Biomarkers Prev* 2010; 19: 729-37.
- [140] Bartsch C, Bartsch H, Jain AK, Laumas KR, Wetterberg L. Urinary melatonin levels in human breast cancer patients. *J Neural Transm* 1981; 52: 281-94.
- [141] Vijayalaxmi, Thomas CR, Jr., Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. *J Clin Oncol* 2002; 20: 2575-601.
- [142] da Silva CJ, Miranda Y, Austin-Brown N, Hsu J, Mathison J, Xiang R, *et al.* Nod1-dependent control of tumor growth. *Proc Natl Acad Sci U S A* 2006; 103: 1840-5.
- [143] Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, *et al.* IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. *Bone Marrow Transplant* 2003; 32: 177-86.
- [144] Tonini G, Nunziata C, Prete SP, Pepponi R, Turriziani M, Masci G, *et al.* Adjuvant treatment of breast cancer: a pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha. *Cancer Immunol Immunother* 1998; 47: 157-66.
- [145] Abrial C, Kwiatkowski F, Chevrier R, Gachon F, Cure H, Chollet P. [Therapeutic potential of melatonin in cancer treatment]. *Pathol Biol (Paris)* 2005; 53: 265-8.
- [146] Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. *Cancer* 1989; 64: 426-33.
- [147] Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, *et al.* Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. *Cancer Res* 2005; 65: 11174-84.
- [148] Blask DE, Dauchy RT, Brainard GC, Hanifin JP. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. *Integr Cancer Ther* 2009; 8: 347-53.
- [149] Karasek M, Kowalski AJ, Zylinska K. Serum melatonin circadian profile in women suffering from the genital tract cancers. *Neuro Endocrinol Lett* 2000; 21: 109-13.
- [150] Bartsch H, Buchberger A, Franz H, Bartsch C, Maidonis I, Mecke D, *et al.* Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay. *Life Sci* 2000; 67: 2953-60.
- [151] Futagami M, Sato S, Sakamoto T, Yokoyama Y, Saito Y. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells. *Gynecol Oncol* 2001; 82: 544-9.

- [152] Zwirner NW, Croci DO, Domaica CI, Rabinovich GA. Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. *Curr Pharm Des* 2010; 16: 255-67.
- [153] Grande C, Firvida JL, Navas V, Casal J. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. *Anticancer Drugs* 2006; 17: 1-12.
- [154] Ramos A, Laguna I, de Lucia ML, Martin-Palomino P, Regodon S, Miguez MP. Evolution of oxidative/nitrosative stress biomarkers during an open-field vaccination procedure in sheep: Effect of melatonin. *Vet Immunol Immunopathol* 2010; 133: 16-24
- [155] Regodon S, Martin-Palomino P, Fernandez-Montesinos R, Herrera JL, Carrascosa-Salmoral MP, Piriz S, et al. The use of melatonin as a vaccine agent. *Vaccine* 2005; 23: 5321-7.
- [156] Zerbini A, Pilli M, Ferrari C, Missale G. Is there a role for immunotherapy in hepatocellular carcinoma? *Dig Liver Dis* 2006; 38: 221-5.
- [157] Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. *J Clin Oncol* 2004; 22: 1389-97.
- [158] Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. *Lancet* 2000; 356: 802-7.
- [159] Reinisch W, Holub M, Katz A, Herneth A, Lichtenberger C, Schoniger-Hekele M, et al. Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma. *J Immunother* 2002; 25: 489-99.
- [160] Martin-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andres O, Gonzalez P, Gonzalez-Gallego J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. *J Pineal Res* 2008; 45: 532-40.
- [161] Ozdemir F, Deniz O, Kaynar K, Arslan M, Kavgaci H, Yildiz B, et al. The effects of melatonin on human hepatoma (Hep G2) cell line. *Bratisl Lek Listy* 2009; 110: 276-9.
- [162] Yan JJ, Shen F, Wang K, Wu MC. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study. *Hepatobiliary Pancreat Dis Int* 2002; 1: 183-6.
- [163] Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Night-shift work and risk of colorectal cancer in the nurses' health study. *J Natl Cancer Inst* 2003; 95: 825-8.
- [164] Farriol M, Venereo Y, Orta X, Castellanos JM, Segovia-Silvestre T. *In vitro* effects of melatonin on cell proliferation in a colon adenocarcinoma line. *J Appl Toxicol* 2000; 20: 21-4.
- [165] Poon AM, Mak AS, Luk HT. Melatonin and ¹²⁵Iiodomelatonin binding sites in the human colon. *Endocr Res* 1996; 22: 77-94.
- [166] Winczyk K, Pawlikowski M, Guerrero JM, Karasek M. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. *Tumour Biol* 2002; 23: 298-302.
- [167] Winczyk K, Fuss-Chmielewska J, Lawnicka H, Pawlikowski M, Karasek M. Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth *in vitro*. *Neuro Endocrinol Lett* 2009; 30: 657-62.
- [168] Tanaka T, Yasui Y, Tanaka M, Tanaka T, Oyama T, Rahman KM. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. *Chem Biol Interact* 2009; 177: 128-36.
- [169] Barni S, Lissoni P, Cazzaniga M, Ardizzioia A, Paolrossi F, Brivio F, et al. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma. *Tumori* 1992; 78: 383-7.
- [170] Lissoni P, Brivio F, Ardizzioia A, Tancini G, Barni S. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. *Tumori* 1993; 79: 401-4.
- [171] Lissoni P, Barni S, Tancini G, Ardizzioia A, Rovelli F, Cazzaniga M, et al. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. *Br J Cancer* 1993; 67: 1404-7.
- [172] Barni S, Lissoni P, Cazzaniga M, Ardizzioia A, Merregalli S, Fossati V, et al. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. *Oncology* 1995; 52: 243-5.
- [173] Vician M, Zeman M, Herichova I, Jurani M, Blazicek P, Matis P. Melatonin content in plasma and large intestine of patients with colorectal carcinoma before and after surgery. *J Pineal Res* 1999; 27: 164-9.
- [174] Muc-Wierzgon M, Nowakowska-Zajdel E, Zubelewicz B, Wierzgon J, Kokot T, Klakla K, et al. Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer. *J Exp Clin Cancer Res* 2003; 22: 171-8.
- [175] Pontes GN, Cardoso EC, Carneiro-Sampaio MM, Markus RP. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppresses nocturnal melatonin production. *J Pineal Res* 2007; 43: 365-71.
- [176] Wenzel U, Nickel A, Daniel H. Melatonin potentiates flavone-induced apoptosis in human colon cancer cells by increasing the level of glycolytic end products. *Int J Cancer* 2005; 116: 236-42.
- [177] Winczyk K, Pawlikowski M, Karasek M. Melatonin and RZR/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer. *J Pineal Res* 2001; 31: 179-82.
- [178] Cos S, Mediavilla MD, Fernandez R, Gonzalez-Lamoun D, Sanchez-Barcelo EJ. Does melatonin induce apoptosis in MCF-7 human breast cancer cells *in vitro*? *J Pineal Res* 2002; 32: 90-6.
- [179] Garcia-Navarro A, Gonzalez-Puga C, Escames G, Lopez LC, Lopez A, Lopez-Cantarero M, et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. *J Pineal Res* 2007; 43: 195-205.
- [180] Buzzell GR. Studies on the effects of the pineal hormone melatonin on an androgen-insensitive rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor. *J Neural Transm* 1988; 72: 131-40.
- [181] Shiu SY, Law IC, Lau KW, Tam PC, Yip AW, Ng WT. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. *J Pineal Res* 2003; 35: 177-82.
- [182] Siu SW, Lau KW, Tam PC, Shiu SY. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. *Prostate* 2002; 52: 106-22.
- [183] Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation *via* a receptor and PKA independent mechanism. *Prostate* 2005; 63: 29-43.
- [184] Park JW, Hwang MS, Suh SI, Baek WK. Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. *J Pineal Res* 2009; 46: 415-21.
- [185] Joo SS, Yoo YM. Melatonin induces apoptotic death in LNCaP cells *via* p38 and JNK pathways: therapeutic implications for prostate cancer. *J Pineal Res* 2009; 47: 8-14.
- [186] Jung-Hynes B, Reiter RJ, Ahmad N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. *J Pineal Res* 2010; 48: 9-19.
- [187] Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. *J Pineal Res* 2010; 49: 60-8.
- [188] Hevia D, Mayo JC, Quiros I, Gomez-Cordoves C, Sainz RM. Monitoring intracellular melatonin levels in human prostate normal and cancer cells by HPLC. *Anal Bioanal Chem* 2010; 397: 1235-44.
- [189] Sanchez-Barcelo EJ, Mediavilla MD, Tan DX, Reiter RJ. Clinical Uses of Melatonin: Evaluation of Human Trials. *Curr Med Chem* 2010; 17: 2070-95.
- [190] Mononen, I., Kelo, E. Method for treatment of cancers or inflammatory diseases. US20100143324 (2010).
- [191] Krusinga, R., Johannes, H. Use of melatonin in the manufacture of a medicament for treating cancer. EP1656939 (2006).
- [192] Baguley, B.C., Ching, L.M., Philpott, M. Cancer treatment by combination therapy. US7510830 (2009) & US7510830 (2009).
- [193] Cavalieri, E., Rogan, E. Unifying mechanism and methods to prevent cancer and neurodegenerative diseases. US20090312391 (2009).
- [194] Slominski, A., Sweatman, T.W., Fischer, T.W. Uses of melatonin in skin. US20070218023 (2007).

- [195] Casper, R., Wardrop, J., Spilkin, J. Use of an optical filter for the prevention of melatonin suppression by light at night. EP1546792 (2010).
- [196] Alpert, M.C., Carmone, E.F., Hansler, R.L. Light emitting diode lamp free of melatonin-suppressing radiation. WO09029575 (2009).
- [197] Alpert, M.C., Carmone, E.F., Hansler, R.L., Kubulins, V. E. Multi-chip light emitting diode light device. US20100244740 (2010).